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Overexpression of fibroblast growth factor 8 (FGF8) mRNA has been previously described in prostate cancer. Of its four isoforms,
FGF8b is thought to be the most important in carcinogenesis. We hypothesised that immunodetection of FGF8b in archival prostate
cancer specimens is of potential prognostic value. Using a selected cohort of prostate tumours from transurethral (n¼30) and radical
prostatectomies (n¼59), an optimised protocol for FGF8b immunoreactivity was used to corroborate expression with clinical
parameters. No expression was observed in benign prostates (n¼10). In prostate cancer, immunoreactivity was localised to the
malignant epithelium with weak signals in the adjacent stroma. Expression of FGF8b in stage T1 and T2 cancers were 40 and 67%,
respectively. In contrast, FGF8b expression was present in 94% of T3 and 100% of T4 cancers. By histological grade, FGF8b was found
in 41% of low-grade cancers (Gleason score 4–6), 60% of intermediate-grade cancers (Gleason score 7 and 92% of high-grade
cancers (Gleason score 8–10). The intensity of expression was significantly associated with stage (P¼0.0004) and grade (Po0.0001)
of disease. We further hypothesised that FGF8b overexpression resulted from enhanced transcription and translation rather than
from abnormalities involving the FGF8 gene locus. This was tested by means of fluorescent in situ hybridisation in 20 cancer
specimens to map the FGF8 gene locus. FGF8 gene copy number in benign and malignant nuclei was found to be similar (2.3370.57
and 2.070.81, respectively P¼0.51). Based on these findings, we propose a multicentre study on cohorts of patients to further
evaluate FGF8b as a potential prognostic marker in prostate cancer.
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Prostate cancer is the second most common cause of cancer deaths
in men in Western countries (Merril et al, 1996; Greenlee et al,
2000). For patients with locally advanced and/or metastatic
disease, hormonal manipulation by androgen blockade is the
mainstay of treatment. In hormone-relapsed disease however,
there are no satisfactory therapeutic options. Targeted therapy of
growth factors has been suggested as a model of treatment in both
early and advanced cancers.
Human fibroblast growth factor 8 (FGF8) is a member of the
fibroblast growth factor (FGF) family of 23 homologous proteins
(Powers et al, 2000) and has been mapped to chromosome 10q24
(Yoshiura et al, 1997). The peptide was first implicated in prostate
cancer when FGF8 mRNA was found to be expressed in prostate
cancer cell lines (Ghosh et al, 1996; Schmitt et al, 1996). In clinical
prostate cancer, overexpression of FGF8 mRNA was found to be
associated with high-grade and late-stage disease (Leung et al,
1996; Dorkin et al, 1999). Subsequent work has shown that distinct
isoforms of FGF8 possess different transforming potential. The
human FGF8 gene comprises six exons (1A–D, 2 and 3) and
alternate splicing in exon 1 produces four potential isoforms; a, b,
e and f. Much attention has been focused on the b isoform because
it exhibits potent in vitro transforming ability (MacArthur et al,
1995a; Ghosh et al, 1996). FGF8b transgenic mice have been shown
to develop mammary and salivary gland tumours (Daphna-lken
et al, 1998), while engineered overexpression of FGF8b in both
prostate and breast cancer cell lines is known to induce a more
aggressive phenotype displaying enhanced invasion and growth
(Rudra-Ganguly et al, 1998; Ruohola et al, 2001).
We tested if an optimised protocol to quantitate FGF8b protein
expression could be developed to study archival prostate cancer
specimens. Using this method, we investigated the hypothesis that
protein expression of the FGF8b isoform is closely associated with
tumour grade and stage. Furthermore, we applied fluorescent in
situ hybridisation (FISH) to study the significance of gene
amplification or rearrangement as a mechanism for FGF8
overexpression.
MATERIALS AND METHODS
Antibody
Mouse monoclonal FGF8b antibody (500mgml
 1), obtained from
R&D systems (Abingdon, UK), specifically recognises mouse and
human FGF8b isoform. This antibody was produced from a mouse
hybridoma in which the immunogen was an Escherichia coli-
derived recombinant mouse FGF8b. We further confirmed
specificity of the antibody by probing for recombinant FGF8b
(rFGF8b – R&D systems) using Western blot analysis (data not
shown).
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Samples were obtained from 59 patients undergoing radical
prostatectomy (RP) with a median age of 62 years (range 38–
71). None had received neo-adjuvant hormonal or chemotherapy
treatment Whole-mount specimens were transected to reveal
cancer foci and/or coincidental areas of high-grade prostatic
intraepithelial neoplasia (HGPIN) and then embedded in paraffin
wax blocks. A further 30 patients with prostate cancer (median age
72, range 56–82 years) diagnosed following transurethral resection
(TUR) of the prostate were identified from a pathology department
database. These patients initially presented with bladder outflow
obstruction and none had prior hormone ablation therapy.
Sections from a further 10 cases of benign prostatic hyperplasia
(BPH) were also obtained from TURP archives and were confirmed
to be histologically nonmalignant. Correlation of FGF8 expression
in radical prostatectomy (RP) specimens were made to the
pathological stage. Data obtained from TUR specimens were
corroborated to their corresponding clinical stage. All cases of
cancer were Gleason graded by a consultant uro-pathologist
(MCR). Serum prostate-specific antigen (PSA) levels (first referral
to the urology clinic or assay performed after surgery) were
obtained from the patient’s records.
Immunohistochemistry
The optimal concentration of FGF8b antibody to be used for
immunostaining was derived from serial dilution (1:100–1:1000)
testing on composite tissue blocks. These blocks included samples
of placenta as well as testis, breast cancer and prostate cancer
known to express FGF8 (Tanaka et al, 1998; Dorkin et al, 1999). A
dilution of 1:500 gave the optimal signals. As a negative control,
sections of bronchus and ileum, which do not express FGF8, were
stained with this concentration of antibody and failed to generate
signals. Sections of prostate were cut at 4 mm from tumour blocks
and mounted onto APES-coated slides. Immunostaining was
performed using a standard biotin/avidin–peroxidase method.
Paraffin sections were baked overnight at 501C, deparaffinised in
xylene and rehydrated through graded alcohols with a final wash
in distilled water. Antigen retrieval was achieved by immersion in
0.01 M sodium citrate buffer (pH 6.0) and microwaving on full
power (1000W) in a microwaveable pressure cooker to achieve
5min at full pressure. Slides were then washed in running tap
water and transferred to phosphate-buffered saline (PBS) pH 7.1
for 5min. Treating sections for 10min in 3% hydrogen peroxide
quenched endogenous peroxidase activity. Slides were then rinsed
in PBS and incubated with 20% normal goat serum in PBS for
10min, followed by overnight incubation in optimally diluted
primary antibody at 41C. Slides were then incubated in secondary
antibody (biotinylated goat anti-mouse, Biogenex) diluted 1:60 in
PBS for 30min at room temperature, rinsed in PBS and then
treated with diaminobenzidine (Biogenex) solution for 5min.
Sections incubated without any primary antibody were also
employed as internal negative controls. All sections were counter-
stained with haematoxylin.
Fluorescent probe manufacture
A human BAC clone from the 10q24 region (bA573E23) (Acc no:
AC016774-clone RP11-573E23) was kindly provided by Dr Mark
Earthrowl (Sanger Centre-Chromosome 10 mapping group, UK).
This BAC clone was selected based on a 100% similarity match
between the FGF8 cDNA sequence and known sequences within
the clone (BLAST (NCBI) program). The clone was colony
polymerase chain reaction (PCR) verified by the distributor and
found to contain the expected markers. Stabs were streaked onto
chloramphenicol (20mgml
 1) plates and grown overnight in a
371C incubator. Following standard extraction, BAC DNA at a
concentration of 1mgml
 1 was labelled using Nick Translation
according to the manufacturer’s protocol (Vysis Inc., IL, USA). In
this procedure, Spectrum Green dUTP was incorporated into the
probe fragments generated. Temperature and timing of the
labelling reaction was set to produce probes of size between 200
and 300bp. As a competitive step, 2ml of salmon sperm DNA
(Sigma, Poole, UK) was added to 10ml of probe and ethanol
precipitated. Pelleted probe was then resuspended in Hybrisol VI
(Oncor, UK) to a concentration of 10ngml
 1. A prelabelled a
satellite probe specific for chromosome 10 (centromere) was
obtained from Oncor, UK.
Fluorescent in situ hybridisation (FISH)
Paraffin tissue sections of prostate cancer (n¼20) and benign
prostatic hyperplasia (n¼10) were predried at 501C overnight
before being dewaxed in xylene and rehydrated in ethanol. To
improve signal intensity, sections were incubated in 1 M sodium
thiosulphate (pH 7.0) for 10min at 751C. Pepsin (0.4%) in 0.2 M
HCl (Sigma, Poole, UK) was used to reverse protein crosslinks
caused by formalin fixation for a period of 26min. Sections were
denatured in 70% formamide (in 2  SSC, pH 7.0) at 751C for
2min before quenching in ice-cold ethanol. Preprepared probe was
denatured at 751C for 5min and 200ng of probe was added to each
section and the slide incubated at 371C overnight in a humidified
chamber. Sections were washed in 2  SSC, then 4  SSC plus
Triton before being counterstained with DAPI (4,6 diamidino-2
phenylindole-2 hydrochloride) in antifade mounting medium
(Vectashield, Vectorlabs, Peterborough, UK).
Slide evaluation
Immunostained sections were studied under a light microscope
without prior knowledge of the clinical details. Sample sections
were first previewed by two independent observers (VJG, MCR)
and interobserver agreement was obtained regarding a grading
system. The level of FGF8b expression was correlated directly with
the strength of the immunoreactivity signal generated and scored
as either absent ( ), weak (+), moderate (++) or strong (+++).
This template was then used for the series as a whole. Where two
or more signal intensities were present in one case, the intensity
with greater than 50% area of staining was taken as the score.
Differences in malignant epithelial expression of FGF8b protein in
relation to clinical parameters were then examined using the
Kruskall–Wallis test. A P-value of o0.05 was taken to indicate
statistical significance and analysis was performed using the Arcus
QuickStat programme. Clinical parameters studied were patholo-
gical or clinical stage, histological grade and serum prostate-
specific antigen (PSA) level. Stage was defined according to the
TNM classification system whereby T1–T2 was classed as organ
confined and T3–T4 as locally advanced. Gleason sum score was
used to assess grade and is the sum of the two predominant grades
(range 1–5) of cancer present in each individual case.
For FISH analysis, signals were visualised using a Digital
Scientific SmartCapture Workstation (Cambridge, UK). Probe
authenticity was first verified on blood lymphocyte metaphase
spreads. Mean chromosome copy number (total number of
hybridisation signals divided by the total number of nuclei) was
used as a measure of the overall chromosome copy number in
paraffin sections. In both benign and cancer cases, this was
determined by probing matched histological sections with a
chromosome 10 centromeric probe. The mean chromosome
counts from at least three tumour areas were used to give an
overall value for each case. For FISH in paraffin sections, copy
number was assessed by counting the number of signals/nuclei in
at least 20 signal-positive nonoverlapping cells in both benign and
malignant tissues. At least three separate fields from each tissue
section were analysed separately.
FGF8b in prostate cancer
VJ Gnanapragasam et al
1433
British Journal of Cancer (2003) 88(9), 1432–1438 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yRESULTS
FGF8b expression and clinical parameters
Among radical prostatectomies (RP), the majority of cases were
organ confined (50 out of 59) and the remaining nine had
extracapsular extension (pT3) (Table 1). In this group, 26 out of 59
cases were low grade (Gleason sum score 4–6), 26 out of 59 were
intermediate grade (Gleason sum score 7) while seven were
high grade (Gleason sum score 8–10). Among transurethral
resected (TUR) specimens, the case mix was different. On clinical
staging, 19 out of 30 were organ confined and 11 out of 30 locally
advanced. By Gleason sum score, five were low grade, seven
intermediate and 18 high grade (Table 1). This latter group
therefore had a tendency towards locally advanced and
higher-grade disease. FGF8b immunoreactivity was found to be
associated with disease stage and grade in the RP group
(Table 1). This group however had few patients with advanced
stage and/or grade cancers and concomitantly the level of
significance was not high (P¼0.01 and 0.03, respectively). In the
TUR group, FGF8b expression was not associated with either
clinical parameter most likely because of a preponderance of
advanced-stage and/or high-grade disease (Table 1). To obtain a
better mix of cases, the RP and TUR cohorts were combined and
then analysed.
FGF8b-negative cases were found predominantly in organ-
confined and low- or intermediate-grade cancers (Table 2). Stage
T1 and T2 cancers expressed FGF8b in 40% (14 out of 35) and 67%
(23 out of 34) of cases, respectively. In T3 and T4 disease, FGF8b
expression was detected in 94% (16 out of 17) and 100% (3 out of
3) of cases, respectively (Table 2). This increase in prevalence was
associated with an increase in signal intensity and FGF8b
immunoreactivity was significantly associated with advanced-stage
disease (P¼0.0004) (Table 2). By histological grade, 41% (13 out
of 31) of low-grade cancers (Gleason score 4–6) expressed FGF8b,
while 60% (20 out of 33) of intermediate-grade cancers (Gleason
score 7) expressed FGF8b (Table 2). High-grade cancers (Gleason
score 8–10) expressed FGF8b in 92% (23 out of 25) of cases. The
level of FGF8b immunoreactivity was significantly associated with
increasing grade of cancer (Po0.0001). Serum PSA levels were
available in 72 out of 89 cases. Analysis of the mean and range of
values in each signal intensity group demonstrated that serum
PSA was not associated with the level of expression of FGF8b
(Table 2).
In summary, these results demonstrate that FGF8b expression is
both stage and grade associated. Where FGF8b was not expressed,
cancers tended to be organ confined and low grade. As cancer
progressed to more advanced and high-grade disease, FGF8b was
found to be more prevalent and expression concomitantly
upregulated.
Table 1 FGF8b staining in radical prostatectomies and transurethral
resections
FGF8b expression
Clinical details – + ++ +++ Total P-value
BPH 10 0 0 0 10 F
Prostate cancer
Stage
RP (n=59)
T1 19 4 2 0 25
T2 10 5 8 2 25
T3 1 4 3 1 9
T4 0 0 0 0 0 0.01
TUR (n=30)
T1 2 0 6 2 10
T2 1 2 4 2 9
T3 0 1 4 3 8
T4 0 0 1 2 3 0.34
Gleason grade
RP (n=59)
4–6 16 7 3 0 26
71 2 5 7 2 2 6
8–10 2 0 3 2 7 0.03
TUR (n=30)
4–6 2 0 3 0 5
71 0 3 3 7
8–10 0 3 9 6 18 0.11
Stage is defined according to the TNM classification system for prostate cancer.
Histological grade was defined by the Gleason score, being the sum of the two
predominant grades of cancer in a section (range 2–10). Grades was then defined as
low (Gleason score 4–6), moderate (Gleason score 7) or high (Gleason score 8–
10). A P-value of less than 0.05 was taken to indicate statistical significance. RP=radical
prostatectomy; TUR=transurethral resection.
Table 2 Intensity of FGF8b expression is associated with stage and grade of prostate cancer
FGF8b expression
Prostate cancer
(RP and TUR) – + ++ +++ Total P-value
Stage (n=89)
T1 21 4 8 2 35
T2 11 7 12 4 34
T3 1 5 7 4 17
T4 0 0 1 2 3 0.0004
Gleason grade (n=89)
4–6 18 7 6 0 31
7 13 5 10 5 33
8–10 2 3 12 8 25 o0.0001
PSA (n=72) 10.2 19.1 35.7 34.1 0.29
Mean value (0.8–25.9) (1.7–154) (1.7–200) (2.8–161)
and range (ngml
 1)
Data from the radical prostatectomy (RP) and transurethral cohorts were combined to analyse the association of FGF8 with
clinical parameters. PSA values in each signal intensity group were also analysed. A P-value of less than 0.05 was taken to
indicate statistical significance. RP=radical prostatectomy; TUR=transurethral resection.
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In samples of benign prostatic hyperplasia (n¼10), no FGF8b
expression was detected (Figure 1A). In radical prostatectomies,
FGF8b was found predominantly in the epithelium of malignant
glands (Figure 1B, C, E). In these cells, we observed that FGF8b was
located primarily in the cytoplasm of epithelial cells with no
expression seen in the nucleus. In the majority of cases, we also
observed patchy signals in the stroma adjacent to FGF8b-
expressing epithelial cells (Figure 1B). This observation is in
keeping with FGF8b being a secreted paracrine peptide. Areas of
normal prostate epithelium in the same slide were invariably
negative for FGF8b expression (Figure 1C). Coincidental areas of
high-grade prostatic intraepithelial neoplasia (HGPIN) were found
adjacent to tumour in 10 radical prostatectomies. Among these,
five cases were negative for FGF8b in both cancer and HGPIN
areas (Figure 1D) and two cases were positive for FGF8b in both
cancer and HGPIN areas. In a further two cases, areas of cancer
expressed FGF8b but coexisting HGPIN did not. There was only
one case in which HGPIN was found to express FGF8b but
coexisting cancer was negative. Among patients diagnosed
following TUR, the majority of tumours were of high-grade
cancer. FGF8b expression was again found predominantly in
malignant epithelium (Figure 1F, G).
FGF8 gene locus is not amplified in malignant cells
The mean chromosome copy number (MCCN) for benign tissue
was 2.070.81 and for malignant tissue 1.6070.54, suggesting that
there was no statistical difference in chromosome 10 copies
between benign and malignant nuclei (Figure 2A, B). Previous
FISH studies have mapped the FGF8 gene to a region within the
10q24 band using blood lymphocyte metaphase spreads (Yoshiura
et al, 1997). Our BAC probe containing the FGF8 sequence was
similarly tested on blood lymphocyte metaphase spreads and
found to hybridise specifically to the 10q24 region (Figure 2C).
Probes were then hybridised to optimally prepared paraffin-
embedded prostate sections. In signal-positive nuclei, there was no
observable difference in the number of hybridisation signals
between benign and malignant cells. The mean number of signals
in benign nuclei was 2.3370.57 (Figure 2D) and for malignant
nuclei 2.070.81 (P¼0.51) (Figure 2E). This suggests that the
region covered by the FISH probe, and by inference its constituent
×100 ×400 ×200
×400 ×400 ×200
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Figure 1 FGF8b expression pattern in prostate cancer. (A) Benign prostate with no staining for FGF8b. (B) Malignant foci (black arrow) of prostate
cancer demonstrating FGF8b positivity in epithelial cells and associated weak stromal signals (yellow arrow). (C) Sections of malignant epithelium adjacent to
benign glands (red arrow). (D) FGF8b-negative high-grade prostatic intraepithelial neoplasia from a radical prostatectomy. (E–G) Sections of prostate
demonstrating low, moderate and high FGF8b expression, respectively, in different histological grades of cancer.
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rearrangement during prostate carcinogenesis.
DISCUSSION
FGFs exert their biological function by binding to high-affinity
tyrosine kinase fibroblast growth factor receptors (FGFR) in the
presence of heparin (Ornitz et al, 1992). Four receptors have been
detailed (designated FGFR 1–4) and multiple splice variants of
these receptors have been described (Ornitz et al, 1996). FGF8 is
known to activate FGFR2, 3 and 4, as well as FGFR1 if applied in
high concentrations (Ornitz et al, 1996; Blunt et al, 1997). In
addition, developmental studies have shown that it is the c splice
forms of FGFRs that are the preferred targets of FGF8 and these are
expressed predominantly in the mesenchymal tissue (MacArthur
et al, 1995b). This suggests that FGF8, commonly secreted by
epithelial cells, interacts with stromal tissue in a paracrine fashion.
The prostate is known to express FGFR1, 2 and 3, while FGFR4 has
only been detected at low levels in prostate cancer cell lines (Story
et al, 1994; Ittman and Mansukhani, 1997; Giri et al, 1999;
Ropiquet et al, 2000). In prostate carcinogenesis, FGFR splicing
characteristics are known to be altered. In early malignancy, for
instance, the FGFR1IIIc isoform is preferentially expressed by
epithelial cells while in more advanced cancers, the FGFR2IIIc
isoform is upregulated (Yan et al, 1992; Kwabi-Addo et al, 2001).
In this context, FGF8 may well adopt both a paracrine and an
autocrine role. The FGF8 isoforms themselves are known to have
relatively specific binding characteristics (Blunt et al, 1997).
Human FGF8a, for example, does not activate any of the FGFRs,
while the FGF8b and e isoforms are known to interact with
FGFR3IIIc and FGFR4 (Blunt et al, 1997). FGF8b however is the
only isoform known to interact with FGFR2IIIc. It is clear that a
more favourable environment for FGF8, and in particular FGF8b
appears to be acquired in cancer progression. This idea is further
supported by evidence of transcript overexpression in metastatic
lesions of prostate cancer (Dorkin et al, 2000).
Previous expression studies, including work from our own
centre, have assayed total FGF8 levels in clinical material (Leung
et al, 1996; Dorkin et al, 1999; Valve et al, 2001). Data concerning
FGF8 correlation with clinical parameters, however, have been
conflicting and may reflect differences in splice form utilisation
(Leung et al, 1996; Tanaka et al, 1998; Dorkin et al, 1999; Valve
et al, 2001). Transcript studies of isoform expression are limited by
reliance on semiquantitative RT–PCR on heterogeneous frozen
materials. To allow quantitative and spatial assessment, we
optimised a protocol for immunohistochemical detection of
FGF8b. The choice of antibody was crucial for this study. We
have previously described the use of the selected FGF8b antibody
in both Western blot and immunohistochemistry studies (Gnana-
pragasam et al, 2002). The specificity and suitability of this
antibody for immunohistochemistry has also been previously
validated in breast cancer (Zammit et al, 2002). Furthermore, the
antibody was shown not to crossreact with other FGFs. In this
study, specificity of the antibody was confirmed and immunor-
eactivity was blocked completely by preabsorption with recombi-
nant FGF8b.
In prostate cancer specimens, we found that FGF8b was
expressed in malignant epithelium and to a lesser extent in the
adjacent stroma. It is possible that FGF8b, secreted by epithelial
×1000 ×1000 ×1000
×2000 ×2000
ABC
E D
Figure 2 FGF8 gene locus analysis. Nuclei and chromosomes are stained blue by DAPI as in Materials and Methods. (A, B) Fluorescent in situ
hybridisation using a chromosome 10 specific probe (red fluorescent) for analysis of the mean chromosome copy number in benign and malignant prostate
sections, respectively. (C) Specific localisation of the green fluorescent-labelled BAC probe to the short arm of chromosome 10 in blood metaphase spreads.
(D) Paraffin FISH using fluorescent-labelled BAC probe in a benign prostate section. (E) Paraffin FISH using fluorescent-labelled BAC probe in prostate
cancer.
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growth factors and cytokines, which in turn stimulate epithelial
cells. This theory is supported by FGFR1IIIc and FGFR3IIIc splice
form expression in the prostatic stroma (Story et al, 1994).
Immunohistochemistry demonstrated that FGF8b protein was
significantly overexpressed in locally advanced and high-grade
tumours. Tanaka et al (1998) have similarly reported frequent
overexpression of FGF8b protein in malignant prostate epithelium.
In a study of 43 needle biopsies of prostate cancer however, the
authors did not observe an association between staining intensity
and clinical parameters. This study however did not use the
Gleason grade and TNM system of disease classification but a
Japanese system of prostate cancer classification. Valve et al
(2001), investigating isoform transcript expression, did not find a
difference in FGF8b levels comparing normal and malignant
prostates using semiquantitative PCR. To explain this, the authors
suggest that FGF8b mRNA in their normal prostates might have
been derived from foci of incidental prostatic intraepithelial
neoplasia (PIN). We similarly observed that in prostate cancer
sections, some coincidental areas of HGPIN demonstrated
positivity for FGF8b. Serum PSA levels were not found to be
associated with FGF8b immunoreactivity.
Loss of heterozygosity (LOH) on the short arm of chromosome
10 has been documented in both familial and sporadic prostate
cancer as well as in HGPIN (Saric et al, 1999; Verhagen et al, 2000;
Sakr and Partin, 2001). Most recently, Latini et al (2001), using
microsatellite markers, have shown LOH of the candidate tumour
suppressor PTEN gene locus (10q23) in advanced prostate cancer.
Using a labelled probe spanning the FGF8 gene locus, FISH
analysis in a series of 20 cancers failed to show evidence of a
change, neither amplification nor rearrangement, within this
region. As both FGF8 mRNA and protein levels are increased in
prostate cancer, this points to transcriptional control of the gene as
a mechanism of regulating expression. In keeping with this, we
have recently demonstrated that the androgen receptor is able to
enhance FGF8 gene promoter activity (Gnanapragasam et al,
2002).
The mechanism by which FGF8 mediates tumorigenesis has
been the subject of much research. Ghosh et al (1996) were the first
to demonstrate that human FGF8b induced marked morphological
transformation in NIH3T3 fibroblast cells and strong tumorigeni-
city of the transfected cells in nude mice. More recently, FGF8b has
been overexpressed in LNCaP prostate cancer cells by infection
with an engineered retroviral construct (Song et al, 2000).
Overexpression of FGF8b doubled LNCaP cell growth and
enhanced anchorage-independent clonogenicity. In addition, while
noninfected LNCaP cells failed to form tumours in nude mice, the
majority of transfected cells (four out of five inoculations)
established multifocal growths. In this context, FGF8b appeared
to function as an autocrine stimulator of growth and proliferation.
The authors also demonstrated that FGF8b-transfected LNCaP
cells were more efficient in migrating through Matrigel basement
membranes. They postulated that this was because of enhanced
secretion of enzymes capable of digesting the extracellular matrix.
In support of this, Ruohola et al (2001) found that MCF7 breast
cancer cells transfected with FGF8b were similarly more invasive
than controls and upregulated the expression of matrix metallo-
proteinase 9. Tumours produced by FGF8b-expressing MCF7 cells
were also shown to be more vascular than untransfected controls
(Ruohola et al, 2001). Mattila et al (2001) have also demonstrated
that FGF8b is able to stimulate migration and sprouting of mouse
brain capillary endothelial cells. In this study, FGF8b promoted
endothelial cell differentiation, organisation of capillary cells into
cords and formation of lumen-like structures. From these data, it is
reasonable to postulate that expression of high levels of FGF8b is
conducive to the induction of a more aggressive malignant
phenotype. Such cancer cells may then display enhanced growth
and invasion as well as have angiogenic-inducing properties.
In conclusion, we demonstrate in this study the first evidence of
an association between FGF8 isoform b protein expression and
clinical prostate cancer. We have shown that the expression of the
b isoform of FGF8 is limited to malignant prostate epithelium, the
adjacent stroma and to occasional areas of HGPIN. Expression is
significantly upregulated in late-stage and high-grade disease, and
appears to occur at the transcriptional level as the gene locus is not
amplified. Taken together, these results show evidence of a role for
FGF8b in mediating prostate cancer progression, and in this
context we believe that FGF8b may have an important role as a
prognostic factor in disease outcome. We now propose a multi-
centre study to further corroborate our findings and to evaluate
the role of FGF8b immunodetection as a prognostic marker in
patients with prostate cancer.
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